中草药

基于微生物组学和代谢组学探究乌梅丸调复胆汁酸平衡阻延结肠炎癌转化的机制

PDF下载

中草药 | 药理与临床 2026,57(10): 3848-3860

收起

中草药 |药理与临床 2026 , 57 (10) : 3848 -3860

基于微生物组学和代谢组学探究乌梅丸调复胆汁酸平衡阻延结肠炎癌转化的机制

全屏

李雪珂^1,2, 罗斯敏¹, 蹇若凡¹, 王钧冬¹, 由凤鸣^1,3, 付西^1,2, 蒋义芳¹

作者信息

通讯作者:

付西

作者简介:

李雪珂: 李雪珂,博士,助理研究员,主要从事中西医结合防治结直肠癌的基础研究。E-mail:cathylxk@whu.edu.cn

Mechanism of Wumei Pill in delaying delays colitis-to-cancer transition and regulating bile acid balance based on microbiomics and metabolomics

LI Xueke, LUO Simin, JIAN Ruofan, WANG Jundong, YOU Fengming, FU Xi, JIANG Yifang

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.10.015

文章导航

摘要

收起

目的运用微生物组学、代谢组学探究乌梅丸延缓结肠炎癌转化的作用机制。方法采用偶氮甲烷（azoxymethane，AOM）/葡聚糖硫酸钠（dextran sulfate sodium，DSS）构建结肠炎癌转化动物模型，将32只C57BL/6J小鼠随机分为对照组、模型组和乌梅丸低、高剂量（11.18、22.36 g/kg）组。通过肠道内窥镜观察、大体标本评估和苏木素-伊红（hematoxylin-eosin，HE）染色评价结肠肿瘤进展与组织病理学变化；ELISA检测血清中白细胞介素-6（interleukin-6，IL-6）、肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α），以及血清与粪便中总胆汁酸（total bile acids，TBA）、胆酸（cholic acid，CA）、脱氧胆酸（deoxycholic acid，DCA）、石胆酸（lithocholic acid，LCA）水平；16S rRNA基因测序技术检测肠道微生物多样性及物种丰度；非靶向代谢组学技术评估代谢物丰度；qRT-PCR法验证裂解梭菌（Clostridium scindens，C. scindens）、海氏梭菌（Clostridium hylemonae，C. hylemonae）、洪氏梭菌（Clostridium hiranonis，C. hiranonis）以及辅酶A转移酶编码基因BaiF表达。结果与模型组比较，乌梅丸干预能够阻延结肠炎癌转化，且乌梅丸低剂量的疗效更佳。低剂量的乌梅丸可显著减少结肠肿瘤数量（P＜0.001），降低结肠炎症评分与肿瘤病理学评分（P＜0.05、0.01），降低血清IL-6、TNF-α水平（P＜0.01、0.001）。微生物组学结果显示，乌梅丸可改善肠道菌群结构，减少梭菌属Clostridium等机会致病菌丰度，同时增加乳酸杆菌属Lactobacillus、罗氏菌属Roseburia等益生菌丰度。非靶向代谢组学结果表明，乌梅丸低剂量组与模型组之间存在82种差异代谢物，显著富集于次级胆汁酸代谢通路。乌梅丸可显著降低血清及粪便中TBA、CA及DCA水平（P＜0.05、0.01、0.001）。qRT-PCR结果进一步证实乌梅丸可抑制C. scindens和C. hylemonae等参与DCA合成的细菌（P＜0.05），并导致BaiF基因表达水平降低（P＜0.001）。结论乌梅丸可通过调复肠道菌群介导的胆汁酸稳态，降低C. scindens等细菌丰度及其脱羟基化功能，减少DCA的生成，从而缓解结肠炎症并延缓炎癌转化进程。

关键词

结肠癌 / 乌梅丸 / 胆汁酸 / 肠道菌群 / 裂解梭菌Clostridium scindens / 海氏梭菌Clostridium hylemonae / 盐酸黄柏碱 / 盐酸黄连碱 / 盐酸小檗碱

Abstract

收起

Objective To investigate the mechanism of Wumei Pill (乌梅丸) in delaying the transformation of colitis cancer using microbiome and metabolomics. Methods A colitis cancer transformation animal model was constructed using azoxymethane (AOM)/dextran sulfate sodium (DSS). A total of 32 C57BL/6J mice were randomly divided into control group, model group, and Wumei Pill low-, high-dose (11.18, 22.36 g/kg) groups. Colonic tumor progression and histopathological changes were evaluated by intestinal endoscopic observation, macroscopic specimen assessment and hematoxylin-eosin (HE) staining. Levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) in serum, and levels of total bile acids (TBA), cholic acid (CA), deoxycholic acid (DCA), lithocholic acid (LCA) in serum and in feces were measured by ELISA. 16S rRNA sequencing technology was used to analyze gut microbial diversity and species abundance. The abundance of metabolites was assessed by non-targeted metabolomics analysis. qRT-PCR was used to verify the expression changes of Clostridium scindens (C. scindens), Clostridium hylemonae (C. hylemonae), Clostridium hiranonis (C. hiranonis) and the coenzyme A transferase encoding gene BaiF. Results Compared with model group, the intervention of Wumei Pill could delay the transformation of colitis cancer, and the therapeutic effect was better at low dose of Wumei Pill. Low dose Wumei Pill could significantly reduce the number of colon tumors (P < 0.001), lower colitis and tumor pathology scores (P < 0.05, 0.01), and lower levels of IL-6 and TNF-α in serum (P < 0.01, 0.001). The microbiological results showed that Wumei Pill could improve the structure of intestinal microbiota, reduce the abundance of opportunistic pathogenic bacteria such as Clostridium, and increase the abundance of probiotics such as Lactobacillus and Roseburia. The non-targeted metabolomics results showed that there were 82 differential metabolites between Wumei Pill low-dose group and model group, significantly enriched in secondary bile acid metabolism pathway. Wumei Pill could significantly reduce the levels of TBA, CA,and DCA in serum and feces (P < 0.05, 0.01, 0.001). qRT PCR results further confirmed that Wumei Pill could inhibit bacteria involved in DCA synthesis such as C. scindens and C. hylmonae (P < 0.05), and lead to a decrease in BaiF gene expression level (P < 0.001). Conclusion Wumei Pill could alleviate colitis and delay the progression of inflammatory cancer by modulating the bile acid homeostasis mediated by gut microbiota, reducing the abundance and dehydroxylation function of bacteria such as C. scindens, and decreasing the production of DCA.

Key words

colitis cancer / Wumei Pill / bile acid / gut microbiota / Clostridium scindens / Clostridium hylemonae / phellodendrine chloride / coptisine hydrochloride / berberine hydrochloride

引用本文

李雪珂, 罗斯敏, 蹇若凡, 王钧冬, 由凤鸣, 付西, 蒋义芳. 基于微生物组学和代谢组学探究乌梅丸调复胆汁酸平衡阻延结肠炎癌转化的机制. 中草药, 2026 , 57 (10) : 3848 -3860 . DOI: 10.7501/j.issn.0253-2670.2026.10.015

LI Xueke, LUO Simin, JIAN Ruofan, WANG Jundong, YOU Fengming, FU Xi, JIANG Yifang. Mechanism of Wumei Pill in delaying delays colitis-to-cancer transition and regulating bile acid balance based on microbiomics and metabolomics[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (10) : 3848 -3860 . DOI: 10.7501/j.issn.0253-2670.2026.10.015

基金

收起

国家自然科学基金资助项目 (82505494); 委校联合创新基金项目 (WXLH202403144)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Ding M L, Yan J B, Chao G Q, et al. Application of artificial intelligence in colorectal cancer screening by colonoscopy: Future prospects (Review) [J]. Oncol Rep, 2023, 50(5): 199.
Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis [J]. Lancet, 2023, 402(10401): 571-584.
Liu T, Zhang Y G, Gao F Y, et al. Mechanism of Hedysari Radix Praeparata cum Melle and Curcumae Rhizoma herb pair in colitis-associated colorectal cancer through the MAPK/NF-κB signaling pathway: An investigation in vivo and in vitro [J]. Front Chem, 2025, 13: 1551722.
Tang F Y, Cao F Y, Lu C, et al. Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression [J]. Cancer Sci, 2022, 113(2): 565-575.
Kaur H, Ali S A, Yan F. Interactions between the gut microbiota-derived functional factors and intestinal epithelial cells-implication in the microbiota-host mutualism [J]. Front Immunol, 2022, 13: 1006081.
Yan S H, Chang J Y, Hao X H, et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora [J]. Phytomedicine, 2022, 102: 154217.
Jaiswal J, Srivastav A K, Kushwaha M, et al. Gut microbial metabolite 4-ethylphenylsulfate is selectively deleterious and anticancer to colon cancer cells [J]. J Med Chem, 2025, 68(10): 10425-10438.
Sun M M, Wu W, Liu Z J, et al. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases [J]. J Gastroenterol, 2017, 52(1): 1-8.
刘宇婧, 徐汉辰, 季光. 胆汁酸驱动消化道炎癌转化及中医药防治策略[J]. 中国科学基金, 2024, 38(3): 461-468.
Farhana L, Nangia-Makker P, Arbit E, et al. Bile acid: A potential inducer of colon cancer stem cells [J]. Stem Cell Res Ther, 2016, 7(1): 181.
Cong J J, Liu P P, Han Z L, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8⁺ T cell effector functions [J]. Immunity, 2024, 57(4): 876-889.e11.
王双瑛, 杨子婧, 孟宇航, 等. 乌梅丸古今文献分析[J]. 中国中药杂志, 2022, 47(14): 3956-3962.
陈浩彬, 林才志. 乌梅丸治疗大肠相关性疾病的研究进展[J]. 中国实验方剂学杂志, 2023, 29(1): 250-257.
李杰, 王紫薇, 邓菊, 等. 乌梅丸治疗结直肠癌可行性探讨[J]. 世界中医药, 2023, 18(8): 1178-1182.
Song Y, Dunkin D, Dahan S, et al. Anti-inflammatory effects of the Chinese herbal formula FAHF-2 in experimental and human IBD [J]. Inflamm Bowel Dis, 2014, 20(1): 144-153.
中华中医药学会《溃疡性结肠炎中医诊疗指南》项目组. 溃疡性结肠炎中医诊疗指南(2023) [J]. 中医杂志, 2024, 65(7): 763-768.
陈念芝, 唐诗韵, 冯媛媛, 等. 乌梅丸通过促进肿瘤相关巨噬细胞M1极化抗转移性结直肠癌的机制[J]. 中国实验方剂学杂志, 2026, 32(1): 92-100.
赵冠宇, 辛蕊华, 仇正英, 等. 基于NLRP3/Caspase-1/GSDMD信号通路研究乌梅丸对溃疡性结肠炎小鼠结肠上皮细胞焦亡的作用机制[J]. 中草药, 2023, 54(24): 8086-8093.
支景琳, 冯媛媛, 刘宁宁, 等. 乌梅丸激活STING促进CD8⁺T细胞浸润活化抗结直肠癌的机制[J]. 上海中医药杂志, 2025, 59(5): 1-7.
Lu Z H, Ding Y, Wang Y J, et al. Early administration of Wumei Wan inhibit myeloid-derived suppressor cells via PI3K/Akt pathway and amino acids metabolism to prevent colitis-associated colorectal cancer [J]. J Ethnopharmacol, 2024, 333: 118260.
Zhang Y L, Yang M J, Yang S S, et al. Wumei Wan remodels the tumor immune microenvironment via the Ido1-KYN-AHR axis in AOM/DSS-induced colorectal cancer model [J]. J Ethnopharmacol, 2025, 353: 120371.
赵冠宇, 辛蕊华, 仇正英, 等. 乌梅丸对溃疡性结肠炎小鼠炎症因子及肠道菌群的影响[J]. 中国现代应用药学, 2024, 41(21): 2929-2937.
卢志华, 蒋峰, 王雨吉, 等. 基于STAT3/SREBP1介导的脂质代谢探讨乌梅丸防治结肠炎相关结直肠癌作用机制[J]. 中华中医药杂志, 2023, 38(10): 4717-4722.
Cui H T, Jin Y T, Wang N, et al. Mechanic evaluation of Wu-Mei-Pill on colitis-associated colorectal cancer: An integrated transcriptomics, metabolomics, and experimental validation study [J]. Phytomedicine, 2024, 128: 155509.
Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate [J]. Cancer Sci, 2003, 94(11): 965-973.
Thaker A I, Shaker A, Rao M S, et al. Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS) [J]. JoVE, 2012(67): 4100.
Meng S, Li Y J, Zang X Z, et al. Effect of TLR2 on the proliferation of inflammation-related colorectal cancer and sporadic colorectal cancer [J]. Cancer Cell Int, 2020, 20(1): 95.
Boivin G P, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: Consensus report and recommendations [J]. Gastroenterology, 2003, 124(3): 762-777.
刘宏, 李佳, 林俊芝, 等. 植物精油及其活性成分防治结直肠癌作用机制的研究进展[J]. 中草药, 2023, 54(3): 956-965.
Karim M R, Iqbal S, Mohammad S, et al. Butyrate’s (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer [J]. Arch Microbiol, 2024, 206(4): 137.
Kang X, Liu C G, Ni Y B, et al. 120Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8⁺ T cells [J]. Gastroenterology, 2023, 164(6): S-19.
Nezhadi J, Lahouty M, Rezaee M A, et al. Clostridium difficile as a potent trigger of colorectal carcinogenesis [J]. Discov Oncol, 2025, 16(1): 910.
Ren Y M, Zhuang Z Y, Xie Y H, et al. BCAA-producing Clostridium symbiosum promotes colorectal tumorigenesis through the modulation of host cholesterol metabolism [J]. Cell Host Microbe, 2024, 32(9): 1519-1535.e7.
Karpiński T M, Ożarowski M, Stasiewicz M. Carcinogenic microbiota and its role in colorectal cancer development [J]. Semin Cancer Biol, 2022, 86: 420-430.
Ridlon J M, Gaskins H R. Another renaissance for bile acid gastrointestinal microbiology [J]. Nat Rev Gastroenterol Hepatol, 2024, 21(5): 348-364.
Reddy B S, Wynder E L. Metabolic epidemiology of colon cancer: Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps [J]. Cancer, 1977, 39(6): 2533-2539.
Gentry E C, Collins S L, Panitchpakdi M, et al. Reverse metabolomics for the discovery of chemical structures from humans [J]. Nature, 2024, 626(7998): 419-426.
Quinn R A, Melnik A V, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations [J]. Nature, 2020, 579(7797): 123-129.
Collins S L, Stine J G, Bisanz J E, et al. Bile acids and the gut microbiota: Metabolic interactions and impacts on disease [J]. Nat Rev Microbiol, 2023, 21(4): 236-247.
Morgan R, Bayat Tork M A, Lin Z T, et al. High-fat diet driven post-operative colon cancer recurrence is dependent upon genetic susceptibility to deoxycholic acid [J]. Cancer Lett, 2025, 631: 217943.
Song X L, An Y P, Chen D F, et al. Microbial metabolite deoxycholic acid promotes vasculogenic mimicry formation in intestinal carcinogenesis [J]. Cancer Sci, 2022, 113(2): 459-477.
Won T H, Arifuzzaman M, Parkhurst C N, et al. Host metabolism balances microbial regulation of bile acid signalling [J]. Nature, 2025, 638(8049): 216-224.
Guzior D V, Okros M, Shivel M, et al. Bile salt hydrolase acyltransferase activity expands bile acid diversity [J]. Nature, 2024, 626(8000): 852-858.
Ridlon J M, Kang D J, Hylemon P B. Isolation and characterization of a bile acid inducible 7α-dehydroxylating operon in Clostridium hylemonae TN271[J]. Anaerobe, 2010, 16(2): 137-146.
Kitahara M, Sakamoto M, Benno Y. PCR detection method of Clostridium scindens and C. hiranonis in human fecal samples [J]. Microbiol Immunol, 2001, 45(3): 263-266.
Alhhazmi A A, Alhamawi R M, Almisned R M, et al. Gut microbial and associated metabolite markers for colorectal cancer diagnosis [J]. Microorganisms, 2023, 11(8): 2037.
Funabashi M, Grove T L, Wang M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome [J]. Nature, 2020, 582(7813): 566-570.
Ridlon J M, Hylemon P B. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium [J]. J Lipid Res, 2012, 53(1): 66-76.

2026年第57卷第10期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.10.015

接收时间：2025-12-23
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-12-23

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.10.015

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT